MSN Templated with L-Dopa Amide Derivatives Outperforms the Efficiency of Free-L-Dopa in Reducing Parkinson’s Behavioral Dysfunction in Mice
This novel strategy may represent a promising alternative to conventional treatment, reducing dose frequency and hence minimizing L-dopa side effects. The results herein emphasize the potential of MSN-based drug delivery systems for PD, providing a basis for future translational research of nanotechnology-based formulations for neurodegenerative disorders.
Authors
- Samuel Martinez‐Erro (ORCID: https://orcid.org/0000-0001-9774-0731)
- Carlos Goicoechea
- Victoria García Morales
- Francisco Navas (ORCID: https://orcid.org/0000-0002-3245-7158)
- Miguel M. García (ORCID: https://orcid.org/0000-0002-6910-0494)
- Mónica Onrubia-Márquez (ORCID: https://orcid.org/0000-0002-0402-5454)
- Carmen Rodríguez-Rivera
- Rafael García-Muñoz
- Nancy A Paniagua
- Antonio Martín
- Justine Delaval
- Eva Mª Sánchez-Robles
- Raúl Sanz
- Lara Merchán-Sánchez
Institutions
- Universidad Rey Juan Carlos (ES)
- École de Biologie Industrielle (FR)
- Instituto de Química Médica (ES)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/ijn.s545116
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00